249 related articles for article (PubMed ID: 33932141)
1. Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
Valind A; Gisselsson D
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1397. PubMed ID: 33932141
[TBL] [Abstract][Full Text] [Related]
2. A novel pyroptosis-related gene signature exhibits distinct immune cells infiltration landscape in Wilms' tumor.
Guo Y; Lu W; Zhang Z; Liu H; Zhang A; Zhang T; Wu Y; Li X; Yang S; Cui Q; Li Z
BMC Pediatr; 2024 Apr; 24(1):279. PubMed ID: 38678251
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.
Kolb EA; Houghton PJ; Kurmasheva RT; Mosse YP; Maris JM; Erickson SW; Guo Y; Teicher BA; Smith MA; Gorlick R
Pediatr Blood Cancer; 2020 May; 67(5):e28098. PubMed ID: 31975571
[TBL] [Abstract][Full Text] [Related]
4. Using Elevated Cholesterol Synthesis as a Prognostic Marker in Wilms' Tumor: A Bioinformatic Analysis.
He Y; Cui X; Lin Y; Wang Y; Wu D; Fang Y
Biomed Res Int; 2021; 2021():8826286. PubMed ID: 33628817
[TBL] [Abstract][Full Text] [Related]
5. RNA expression of the WT1 gene in Wilms' tumors in relation to histology.
Miwa H; Tomlinson GE; Timmons CF; Huff V; Cohn SL; Strong LC; Saunders GF
J Natl Cancer Inst; 1992 Feb; 84(3):181-7. PubMed ID: 1311774
[TBL] [Abstract][Full Text] [Related]
6. Immune expression in children with Wilms tumor: a pilot study.
Holl EK; Routh JC; Johnston AW; Frazier V; Rice HE; Tracy ET; Nair SK
J Pediatr Urol; 2019 Oct; 15(5):441.e1-441.e8. PubMed ID: 30981637
[TBL] [Abstract][Full Text] [Related]
7. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
Higgs EF; Bao R; Hatogai K; Gajewski TF
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705315
[TBL] [Abstract][Full Text] [Related]
8. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
[TBL] [Abstract][Full Text] [Related]
9. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
10. Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues.
Yoo SH; Yun J; Keam B; Hong SP; Ock CY; Koh J; Kim S; Jeon YK; Jung KC; Kim M; Kim TM; Kim DW; Kim JI; Heo DS
Cancer Immunol Immunother; 2021 Jun; 70(6):1755-1769. PubMed ID: 33389015
[TBL] [Abstract][Full Text] [Related]
11. Multidimensional Transcriptomics Unveils RNF34 as a Prognostic Biomarker and Potential Indicator of Chemotherapy Sensitivity in Wilms' Tumour.
Zheng J; Liu F; Tuo J; Chen S; Su J; Ou X; Ding M; Chen H; Shi B; Li Y; Chen X; Wang C; Su C
Mol Biotechnol; 2024 May; 66(5):1132-1143. PubMed ID: 38195816
[TBL] [Abstract][Full Text] [Related]
12. CD8+ T-cell lymphocytes infiltration predict clinical outcomes in Wilms' tumor.
Mardanpour K; Rahbar M; Mardanpour S; Mardanpour N; Rezaei M
Tumour Biol; 2020 Dec; 42(12):1010428320975976. PubMed ID: 33283684
[TBL] [Abstract][Full Text] [Related]
13. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
14. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
[TBL] [Abstract][Full Text] [Related]
15. Berberine inhibits Wilms' tumor cell progression through upregulation of Wilms' tumor gene on the X chromosome.
Liu Y; Liu S
Mol Med Rep; 2013 Nov; 8(5):1537-41. PubMed ID: 24002362
[TBL] [Abstract][Full Text] [Related]
16. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.
Ortiz MV; Ahmed S; Burns M; Henssen AG; Hollmann TJ; MacArthur I; Gunasekera S; Gaewsky L; Bradwin G; Ryan J; Letai A; He Y; Naranjo A; Chi YY; LaQuaglia M; Heaton T; Cifani P; Dome JS; Gadd S; Perlman E; Mullen E; Steen H; Kentsis A
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391345
[TBL] [Abstract][Full Text] [Related]
17. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target.
Pode-Shakked N; Harari-Steinberg O; Haberman-Ziv Y; Rom-Gross E; Bahar S; Omer D; Metsuyanim S; Buzhor E; Jacob-Hirsch J; Goldstein RS; Mark-Danieli M; Dekel B
Oncogene; 2011 Apr; 30(14):1664-80. PubMed ID: 21472018
[TBL] [Abstract][Full Text] [Related]
18. Association of E2F3 expression with clinicopathological features of Wilms' tumors.
An Q; Wang Y; An R; Li Y; Yao T; Zhai B; Sun X
J Pediatr Surg; 2013 Nov; 48(11):2187-93. PubMed ID: 24210184
[TBL] [Abstract][Full Text] [Related]
19. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
